MedTrace Logo

A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

NCT02623595 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-10-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe, effective in the treatment of stage IV NSCLC patients who failed in second-line chemotherapy.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

RADIATION

Stereotactic body radiotherapy

A type of radiation therapy

DRUG

rhGM-CSF

Immune modulating agents

Sponsors & Collaborators

  • Tongji Hospital

    collaborator OTHER

  • Hubei Cancer Hospital

    collaborator OTHER

  • Wuhan University

    lead OTHER

Principal Investigators

  • Conghua Xie, MD, PhD · Zhongnan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2019-05-31
Completion
2019-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02623595 on ClinicalTrials.gov